Obama’s Nasty Effect on Pharmaceutical Companies
Jul 16th, 2008 | By Charles Delvalle | Category: Stock Market InvestingSome of the most solid opportunities in the stock market are those that happen because of politics. Let’s face it, the government controls billions of dollars and could make or break industries. The effect an Obama presidency could have on Pharmaceutical companies is one you should be well aware of.
As many of you may know, Barack Obama (and democrats in general) is in favor of importing medicines from overseas, allowing the government to negotiate lower prices with drug companies, and increasing the use of generics. Sounds good for us, but not for big pharmaceutical companies.
First, if the use of generics increases, that means big pharmaceutical companies will make less sales. Second, drug companies charge Americans up to two times more for medicine than European or Canadians. If they have to cut those profits in half because the U.S. negotiated lower prices, that means they receive less profits. If they receive fewer profits you can be sure that their stock prices will fall.
So do yourself a favor and stay away from pharmaceutical companies until after November 11.
Source: Obama’s Nasty Effect on Pharmaceutical Companies
Advertisement
Wall Street wants you to believe that you have to entrust your money with the professionals and all their skills, resources and systems, if you want to make money in the markets. It’s what these guys do for a living! How could you possibly beat them?!
Nothing could be further from the truth. In fact, I have used an embarrassingly simple secret to make $15,048 in just 30 days... and boost my overall account balance 152% in less than a year.
Keep reading to learn how you could join me each month...
Charles Delvalle is a self-taught market-timing professional and value analyst who's followed and invested in the market for the past ten years. He uses a unique combination of technical and fundamental research to pinpoint rapid profit opportunities with stocks and options.
Charles is also a staunch contrarian and takes pride in finding undervalued sectors and discovering undervalued, cash-rich companies. He frequently mocks government stupidities and points out the "inaccuracies (or lies, take your pick) that government reporting frequently dispels as "truth".
